dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Valderrama, A. |
dc.contributor.author | Fuchs, Charles |
dc.contributor.author | Shitara, Kohei |
dc.contributor.author | Janjigian, Yelena |
dc.contributor.author | Alsina Maqueda, Maria |
dc.contributor.author | Bang, Yung-Jue |
dc.date.accessioned | 2022-04-22T12:41:55Z |
dc.date.available | 2022-04-22T12:41:55Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Van Cutsem E, Valderrama A, Bang YJ, Fuchs CS, Shitara K, Janjigian YY, et al. Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. ESMO Open. 2021 Aug;6(4):100189. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7369 |
dc.description | Càncer gàstric; Pembrolizumab; Qualitat de vida |
dc.description.sponsorship | This work was supported by Merck Sharp & Dohme Corp. (no grant number), a subsidiary of Merck & Co., Inc. (no grant number), Kenilworth, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Adenocarcinoma - Tractament |
dc.subject | Esòfag - Càncer - Tractament |
dc.subject.mesh | Adenocarcinoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Esophagogastric Junction |
dc.title | Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100189 |
dc.subject.decs | adenocarcinoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | unión esofagogástrica |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100189 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Van Cutsem E] Department of Digestive Oncology, University Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Valderrama A] Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, USA. [Bang YJ] Department of Biomedical Research, Seoul National University College of Medicine, Seoul, South Korea. [Fuchs CS] Department of Internal Medicine: Hematology, Medical Oncology, Gastro-oncology, Yale University Cancer Center, Smilow Cancer Hospital, New Haven, USA. [Shitara K] Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [Janjigian YY] Department of Gastrointestinal Oncology, Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Alsina M] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34371381 |
dc.identifier.wos | 000703610200012 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |